SpeeDx Ltd. of London at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

SpeeDx Ltd.

152-160, City Road, EC1V 2NX London
United Kingdom of Great Britain and Northern Ireland

Hall map

MEDICA 2019 hall map (Hall 1): stand E33

Fairground map

MEDICA 2019 fairground map: Hall 1

Contact

Terry Sunderland

European Sales Manager

Phone
+447581322518

Email
terrys@speedx.com.au

Warwick Need

Director of Sales

Phone
+61 (0)424 336 577

Email
warwickn@speedx.com.au

Visit us

Hall 1 / E33

18.11.2019

Topic

10:00

Infectious Disease Molecular Diagnostics

Novel qPCR muliplex technology with unique simulataneous antibiotic resistance determination.
Actively seeking distribution partners who have experience with molecular tests
-France
-Spain
-Portugal
-Israel
-Hong Kong
-South East Asia
-Africa

More Less

19.11.2019

Topic

10:00

Infectious Disease Molecular Diagnostics

Novel qPCR muliplex technology with unique simulataneous antibiotic resistance determination.
Actively seeking distribution partners who have experience with molecular tests
-France
-Spain
-Portugal
-Israel
-Hong Kong
-South East Asia
-Africa

More Less

20.11.2019

Topic

10:00

Infectious Disease Molecular Diagnostics

Novel qPCR muliplex technology with unique simulataneous antibiotic resistance determination.
Actively seeking distribution partners who have experience with molecular tests
-France
-Spain
-Portugal
-Israel
-Hong Kong
-South East Asia
-Africa

More Less

21.11.2019

Topic

10:00

Infectious Disease Molecular Diagnostics

Novel qPCR muliplex technology with unique simulataneous antibiotic resistance determination.
Actively seeking distribution partners who have experience with molecular tests
-France
-Spain
-Portugal
-Israel
-Hong Kong
-South East Asia
-Africa

More Less

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing
  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Our products

Product category: DNA testing, Polymerase chain reaction (PCR)

PlexPCR® VHS

PlexPCR VHS* is a multiplex qPCR test for detection and differentiation of HSV-1, HSV-2, VZV & Treponema pallidum
(Syphilis) from genital and non-genital swabs. Proprietary PlexZyme® technology provides 4-levels of specificity and market-leading performance to streamline your lesion testing workflow.Challenges of lesion diagnostics

More Less

Product category: DNA testing, Polymerase chain reaction (PCR)

ResistancePlus GC

ResistancePlus GC* is a multiplex qPCR test for detection of Neisseria gonorrhoeae and sequences linked to ciprofloxacin susceptibility, validated for a range of specimen types. Dual N. gonorrhoeae targets improve clinical specificity. Ciprofloxacin resistance and susceptibility targets are included for additional confidence. ResistancePlus GC* is powered by proprietary PlexPCR® technologies demonstrating improved multiplex performance compared with other probe-based tests.

More Less

Product category: DNA testing, Polymerase chain reaction (PCR)

ResistancePlus MG

ResistancePlus MG* is a multiplex qPCR test for detection of Mycoplasma genitalium and five macrolide resistance markers from male and female urine and swab specimens. Proprietary PlexZyme® and PlexPrime® technologies improve multiplex performance compared with other probe-based tests allowing for multiple mutation detection in a single well.

More Less

Company news

Date

Topic

Download

Nov 14, 2019

FIND Collaborate with SpeeDx and QuantuMDx

The Foundation for Innovative New Diagnostics (FIND) are supporting a collaboration with SpeeDx and QuantuMDx to assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs).

FIND defined the key project in response to urgently needed solutions for POC diagnosis of gonorrhoea as well as susceptibility to existing antibiotics, and is part of a stewardship plan by the World Health organisation (WHO) and the Global Antibiotic Research Development Project (GARDP) for current as well as new drugs.

“We are excited by this collaboration with QuantuMDx and the potential to expand access to high quality testing options to the areas of the world that really need it,” said Dr. Elisa Mokany, SpeeDx Founder and Chief Technology Officer. “Patients around the globe are already benefiting from the clinically relevant information provided by SpeeDx tests, but we are cognisant that the current platforms and processes in use to run these tests do not readily translate to all regions of the world.”

More Less

Sep 6, 2019

SpeeDx Receives CE-IVD Clearance for ResistancePlus® MG FleXible

ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance, and is the first to be launched under Cepheid’s FleXible Cartridge programme.

ResistancePlus® MG FleXible is a near-patient test providing clinically relevant information to help manage the growing problem of macrolide resistance in Mgen infections.

“SpeeDx offers unique technology for simultaneous detection of pathogens and drug resistance directly from clinical specimens. Together, we have leveraged the open architecture of our new FleXible cartridge to enable detection of this emerging drug-resistant pathogen on the GeneXpert System,” said David H. Persing, M.D., Ph.D., Cepheid’s Chief Medical and Technology Officer.

Timely detection of antibiotic resistant infections enables Resistance Guided Therapy, resulting in better treatment of the disease for patients, reduced potential for spreading infection among vulnerable populations, and supporting antibiotic stewardship to combat rising antibiotic resistance.

More Less

Aug 6, 2019

SpeeDx Raise US $15 million Equity from Northpond Ventures

Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets. SpeeDx collaborates with key researchers and organizations around the globe with a shared goal of providing clinicians with the information and guidance they need to address the urgent issues related to antibiotic resistance and better management of infectious diseases.

“SpeeDx has developed significant strategic partnerships and their recent successes demonstrate true global potential,” said Michael Rubin M.D., Ph.D., Founder and CEO of Northpond Ventures. “They are positioned to become a world leader with technology that will benefit millions of patients globally.”

More Less

About us

Company details

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.

SpeeDx Vision
To innovate clinical diagnostic approaches for improved delivery, reduced costs, and better patient outcome.


SpeeDx Mission
Empowering practitioners to make informed clinical decisions for improved patient outcomes.


SpeeDx Quality Policy
SpeeDx has a quality mission to consistently meet the needs and expectations of customers, commercial partners, and regulators in the following way:

SpeeDx will comply with ISO 13485, IVDD (EU), QSR (US FDA),  MDR (Health Canada), TGR 2002 (Australian TGA) and any other regulatory requirements as they arise; our Quality System effectiveness will be reviewed and maintained by management.

SpeeDx will endeavour to improve the health and safety of customers by continuing to invest in product development activities with the aim of producing in vitro diagnostic medical devices and research use only products for the detection of nucleic acids.

A company-wide culture committed to quality will be supported by management with the establishment and continuous review of quality objectives.

Achievement of this goal involves all staff, each of whom are individually responsible for the quality of their work, resulting in a continually improving work environment and a continually improving Quality Management System. Management at every level has an additional responsibility to ensure quality is instilled in all levels of the organisation, and in all activities.

More Less